Related Experiment Video
Updated: Mar 29, 2026
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic
Lin Zhang1, Miaozhen Qiu2, Ying Jin3
1Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou 510060, China.
Background:
Targeting the immune checkpoints in solid tumors becomes hot recently. Programmed cell death ligand 1 (PD-L1) is ligand for programmed death 1 (PD-1), which is known to negatively regulate T-cell activation. In the present study, we investigated the expression of PD-L1 in tumor specimens of gastric cancer and its relationships with clinicopathological variables and survival.
Methods:
The expression of PD-L1 in 132 surgically resected specimens of stage II and III gastric cancer was evaluated by immunohistochemistry in microarray tissue.
Results:
Expression of PD-L1 was observed in 50.8% (67/132) of gastric cancer tumor specimens. Patients whose tumor size over 5cm had a higher positive rate of PD-L1 expression. There was no relationship between the expression of PD-L1 and other clinicopathological variables including age, gender, clinical stage, location as well as histological differentiation. PD-L1 positive patients had significantly poorer survival than negative patients. The 5-year survival rates was 83.1% in those with PD-L1 negative patients and 50.7% for PD-L1 positive patients (P<0.001). The multivariate analysis indicated that both PD-L1 positive and Tumor-node-metastasis stage were independent prognostic factors in gastric cancer patients (P=0.001 and 0.025, respectively).
Conclusions:
The expression of PD-L1 was found in half of stages II and III gastric cancer patients. Positive of PD-L1 expression indicated poor survival in Chinese stages II and III gastric adenocarcinoma patients. These results may provide the clue for immunotherapy in the adjuvant treatment setting of gastric cancer patients.
Insights
Programmed cell death ligand 1 (PD-L1) expression in gastric cancer is linked to poorer survival. This finding suggests PD-L1 may guide immunotherapy decisions for stage II and III gastric adenocarcinoma patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immune checkpoint targeting is a key strategy in solid tumor treatment.
- Programmed cell death ligand 1 (PD-L1) negatively regulates T-cell activation.
- Understanding PD-L1 expression in gastric cancer is crucial for therapeutic development.
Purpose of the Study:
- To investigate PD-L1 expression in gastric cancer.
- To correlate PD-L1 expression with clinicopathological variables and patient survival.
Main Methods:
- Immunohistochemistry was used to evaluate PD-L1 expression.
- 132 surgically resected specimens of stage II and III gastric cancer were analyzed.
- Microarray tissue technique was employed.
Main Results:
- PD-L1 expression was detected in 50.8% of gastric cancer specimens.
- Larger tumor size (>5cm) correlated with higher PD-L1 positivity.
- PD-L1 positive patients exhibited significantly poorer survival rates (5-year survival: 50.7% vs. 83.1%).
- PD-L1 positivity and Tumor-node-metastasis stage were independent prognostic factors.
Conclusions:
- PD-L1 is expressed in approximately half of stage II and III gastric cancer patients.
- Positive PD-L1 expression is associated with poor survival in Chinese gastric adenocarcinoma patients.
- These findings may inform immunotherapy strategies in adjuvant gastric cancer treatment.
Related Concept Videos
02:23Abnormal Proliferation
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...